Expanding the phenotypic and allelic spectrum of SMG8: Clinical observations reveal overlap with SMG9‐associated disease trait

SMG8 (MIM *617315) is a regulatory subunit involved in nonsense‐mediated mRNA decay (NMD), a cellular protective pathway that regulates mRNA transcription, transcript stability, and degrades transcripts containing premature stop codons. SMG8 binds SMG9 and SMG1 to form the SMG1C complex and inhibit...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part A Vol. 188; no. 2; pp. 648 - 657
Main Authors Abdel‐Salam, Ghada M. H., Duan, Ruizhi, Abdel‐Hamid, Mohamed S., Sayed, Inas S. M., Jhangiani, Shalini N., Khan, Ziad, Du, Haowei, Gibbs, Richard A., Posey, Jennifer E., Marafi, Dana, Lupski, James R.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.02.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:SMG8 (MIM *617315) is a regulatory subunit involved in nonsense‐mediated mRNA decay (NMD), a cellular protective pathway that regulates mRNA transcription, transcript stability, and degrades transcripts containing premature stop codons. SMG8 binds SMG9 and SMG1 to form the SMG1C complex and inhibit the kinase activity of SMG1. Biallelic deleterious variants in SMG9 are known to cause a heart and brain malformation syndrome (HBMS; MIM #616920), whereas biallelic deleterious variants in SMG8 were recently described to cause a novel neurodevelopmental disorder (NDD) with dysmorphic facies and cataracts, now defined as Alzahrani–Kuwahara syndrome (ALKUS: MIM #619268). Only eight subjects from four families with ALKUS have been described to date. Through research reanalysis of a nondiagnostic clinical exome, we identified a subject from a fifth unrelated family with a homozygous deleterious variant in SMG8 and features consistent with ALKUS. Interestingly, the subject also had unilateral microphthalmia, a clinical feature that has been described in SMG9‐related disorder. Our study expands the phenotypic spectrum of SMG8‐related disorder, demonstrates an overlapping phenotype between SMG8‐ and SMG9‐related rare disease traits, provides further evidence for the SMG8 and SMG9 protein interactions, and highlights the importance of revisiting nondiagnostic exome data to identify and affirm emerging novel genes for rare disease traits.
Bibliography:Funding information
This project was funded by the following grants: a Medical Genetics Research Fellowship Program through the United States National Institute of Health, Grant/Award Number: T32 GM007526‐42; U.S. NHGRI to Baylor College of Medicine Genomic Research to Elucidate the Genetics of Rare (BCM‐GREGoR), Grant/Award Number: U01 HG011758; US National Human Genome Research Institute (NHGRI) and US National Heart Lung and Blood Institute (NHBLI) to the Baylor‐Hopkins Center for Mendelian Genomics, Grant/Award Number: UM1 HG006542; NHGRI K08, Grant/Award Number: HG008986; U.S. National Institute of Neurological Disorders and Stroke, Grant/Award Number: R35NS105078; Muscular Dystrophy Association, Grant/Award Number: 512848; US National Institute of Neurological Disorders and Stroke; US National Human Genome Research Institute
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1552-4825
1552-4833
1552-4833
DOI:10.1002/ajmg.a.62561